Some Issues in the Design and Analysis of Equivalence Trials
- 1 January 1999
- journal article
- Published by Springer Science and Business Media LLC in Drug Information Journal
- Vol. 33 (1), 109-118
- https://doi.org/10.1177/009286159903300114
Abstract
Given the number of approved drugs, it is increasingly the case that the comparison arm for a new drug or combination product is another drug or combination, that is, the trial uses an “active-control.” Such active-controlled trials raise issues not seen in placebo-controlled trials. This note reviews and discusses some issues associated with the design and analysis of equivalence trials. Included are discussions of the choice of the equivalence allowance in designing the trial, and the roles of confidence intervals and intent-to-treat analyses.Keywords
This publication has 23 references indexed in Scilit:
- Comparison of tests and sample size formulae for proving therapeutic equivalence based on the difference of binomial probabilitiesStatistics in Medicine, 1995
- On Approximate and Exact Sample Sizes of Equivalence Tests for Binomial ProportionsBiometrical Journal, 1994
- Inherent difficulties with active control equivalence studiesStatistics in Medicine, 1993
- On population and individual bioequivalenceStatistics in Medicine, 1993
- Bioequivalence revisitedStatistics in Medicine, 1992
- On the use of the generalized t and generalized rank‐sum statistics in medical researchStatistics in Medicine, 1992
- Methodological standards for assessing therapeutic equivalenceJournal of Clinical Epidemiology, 1991
- Consideration of individual bioequivalenceJournal of Pharmacokinetics and Biopharmaceutics, 1990
- A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailabilityJournal of Pharmacokinetics and Biopharmaceutics, 1987
- Confidence intervals rather than P values: estimation rather than hypothesis testing.BMJ, 1986